Transcorneal electrostimulation
DeviceWeekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
Other names: OkuStim, TES, TcES
NCT Number: NCT01835002
The purpose of this study is to expand the safety assessment of repeated applications of an electrical current from a DTL-like electrode in patients with RP.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Glostrup Hospital and Kennedy Center, Glostrup Municipality, Denmark
This is a single-arm open label interventional safety trial with RP patients, who receive weekly TES for 6 months on 1 eye followed by observation for another 6 months without stimulation. The primary outcome measure is safety, indicated by the frequency and severity of adverse events.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
Other names: OkuStim, TES, TcES
Time frame: 6 months
visual acuity slit lamp microscopy for examination of the anterior and posterior segment intraocular pressure measurement visual field examination Optical coherence tomography (OCT) Digital colour fundus photography
Time frame: 6 months
Questionnaires to collect the patient's perceived benefits of treatment and handling of the device
Okuvision GmbH
Industry
Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Multicenter Safety Study of the Okustim ® System
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03374657
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Stockholm, Sweden
View Trial DetailsNCT05282953
Choroid Diseases, Choroideremia
Sydney, New South Wales, Australia
View Trial DetailsNCT05392179
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Durham, North Carolina, United States
View Trial DetailsNCT00378742
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Bethesda, Maryland, United States
View Trial Details